UROwebinar: New perspectives on antibody-drug conjugates as targeted therapy: From basics to clinical practice
The experts will discuss the role of ADCs in urological malignancies with a special focus on urothelial cancer, particularly those targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), providing insights into their potential to enhance treatment precision.
Organiser | European School of Urology |
---|---|
CME | 1.00 |
Location | Online |
Faculty

Dr. G. Gandaglia (IT)
Moderator

Prof. C. Jeronimo (PT)
Moderator

Dr. D. Raggi (GB)
Speaker

Prof. J. Bellmunt (US)
Speaker